Company Filing History:
2 out of 272 
2 out of 59 
1 out of 257 
Years Active: 2014-2019
Title: Steve Granger: Innovator in Biopharmaceuticals
Introduction
Steve Granger is a notable inventor based in Encinitas, California. He has made significant contributions to the field of biopharmaceuticals, particularly through his innovative patents. With a total of three patents to his name, Granger's work focuses on advancing therapeutic solutions.
Latest Patents
One of Granger's latest patents is titled "Antibody-fynomer conjugates." This invention provides a bi-specific fusion polypeptide that comprises a fynomer sequence binding to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence that binds to the interleukin-6 receptor (IL-6R). The fusion polypeptide can effectively bind to both IL-17a and IL-6R, thereby suppressing, reducing, decreasing, inhibiting, or blocking the activities of both IL-17a and IL-6R. Another significant patent is "Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same." This invention relates to antibodies that specifically bind to the poxvirus B5R envelope protein and the poxvirus H3L envelope protein, along with their subsequences and combinations.
Career Highlights
Throughout his career, Granger has worked with prominent organizations, including Kyowa Hakko Kirin Co., Limited and the La Jolla Institute for Allergy and Immunology. His work in these institutions has allowed him to contribute to groundbreaking research and development in the biopharmaceutical sector.
Collaborations
Granger has collaborated with esteemed colleagues such as Shinichiro Kato and Shane Crotty. These partnerships have further enhanced his research capabilities and innovation potential.
Conclusion
Steve Granger's contributions to biopharmaceuticals through his patents and collaborations highlight his role as a significant innovator in the field. His work continues to impact therapeutic advancements and improve health outcomes.